We’ve seen remarkable progress in treating hormone receptor-positive (HR+) metastatic breast cancer (MBC), with numerous new targeted therapies becoming available in recent years. But the work isn’t over yet.
In this episode of Breast Cancer Breakthroughs, we are joined by MBC patient advocate Bethany Adair; Komen grantee and medical oncologist Sonya Reid, M.D.; and medical oncologist Komal Jhaveri, M.D., to discuss today’s treatment approach, reflect on the advances that have broadened options for patients and explore emerging developments that could shape the future of care.
Bethany’s HR+ MBC Diagnosis
Bethany Adair was diagnosed with stage 2 HR+, HER2- breast cancer at the age of 34. “I was young, healthy. I worked in wellness as a yoga therapist. I have no family history of breast cancer, so it was not something that was on my radar,” she recalls. Following a rigorous two-year treatment plan, she had no evidence of disease and moved on with her life.
But five and a half years later, Bethany started having back pain and went in for an MRI. “Two hours later, the doctor called and his first words took my breath away. He said, ‘Bethany, are you sitting down? There are lesions all over your spine. The cancer’s back. You have to call your oncologist right away.’ And I later learned through more testing; it [had] spread throughout my bones, liver, various lymph nodes throughout my body, including my stomach,” says Bethany.
While Bethany’s story is uniquely her own, it’s also a similar experience to many patients, where the initial treatment plan works, but the cancer eventually returns (called recurrence) and/or progresses (when the existing cancer grows and/or spreads).
Hear additional stories from others living with MBC in the video link below.
Although the chance of recurrence for HR+ breast cancer in any given year may be low, it can return many years after treatment. Among the breast cancer subtypes, it carries the greatest risk of late recurrence (when it is more than five years after initial diagnosis and treatment).
Treatment of HR+ Metastatic Breast Cancer
HR+ breast cancer accounts for approximately 70 to 80% of MBC cases. Growth and spread of these cancers is driven by hormone (estrogen and/or progesterone) signaling. This means these cancers have high levels of estrogen receptor (known as ER+) and/or the progesterone receptor (known as PR+). As a result, targeted treatments consist of hormone (endocrine) therapies that work by preventing the hormone from binding to its receptor, by lowering hormone levels, or by causing destruction of the hormone receptor.
Today, first-line treatment for HR+, HER2- MBC typically includes treatment with two drugs: 1) hormone therapy, such as an aromatase inhibitor or tamoxifen, plus 2) CDK4/6 inhibitor (CDK4/6i), such as palbociclib, ribociclib or abemacicilb. When these drugs are used in combination, patients experience improved progression-free survival and overall survival. Unfortunately, many patients develop resistance to first-line treatment, where it’s no longer effective. This leads to disease progression.
Advances in Care: New Possibilities for Patients
Many new drugs have been developed over the past several years that help address treatment resistance that occurs during first-line treatment. Dr. Reid says, “It’s critical for patients with HR+ MBC to look for mutations that are driving resistance.” This is because the mutation driving resistance dictates the next line of treatment.
Biomarker testing includes testing for mutations in the PIK3CA, AKT1, PTEN and ESR1 genes. If a mutation is identified, the patient and their oncologist can discuss the most optimal treatment strategy for targeting that mutation and stopping cancer progression.
For example, individuals with PIK3CA gene mutations may receive alpelisib plus fulvestrant (hormone therapy) as their second-line treatment. For individuals with ESR1 mutations, several new treatment options are available, including oral SERDs as a second-line treatment (elacestrant, imlunestrant) and a PROTAC (vepdegestrant).
The latest approval for second-line treatment of HR+ MBC came following results from the EMBER-3 trial. In 2025, imlunestrant was approved as a monotherapy for ESR1-mutant, HR+, HER2- MBC following EMBER-3 trial results. Just last month, the FDA approved combination imlunestrant plus abemaciclib for individuals with ESR1-mutant, HR+, HER2- MBC because of favorable results from the EMBER-3 trial. This combination of treatment is what Bethany is taking now as her sixth-line of treatment.
Each patient responds differently to a treatment plan, but for Bethany, she had an amazing response to imlunestrant and abemaciclib. “I had a complete metabolic response in my liver and then a lot of improvement in my bones,” she says. Bethany had to lower the abemaciclib dose to lessen the side effects, but overall, her quality of life has been excellent while under treatment.
HER2 Status Matters
Despite her original diagnosis of HR+, HER2- MBC, Bethany became eligible for the HER2-targeting antibody drug conjugate called trastuzumab-deruxtecan (Enhertu). This is because recent research findings show that some patients labeled as being ‘HER2-negative’ may have low or ultralow levels of HER2, making them eligible for HER2-targeting agents.
“It is something that I would not have had access to five or six years ago,” she says. “However, thanks to research, there’s this new middle ground of being HER2-low or ultralow. And so, I always tell people like, ‘Hey, if you think you’re HER2-negative, ask your doctor about being HER2-low or ultralow.’ I went to my pathology report, I looked at my IHC score where it tells you you’re HER2-negative, and it said 1+. And I said, ‘I’m HER2-low.’ So, that opened doors to a treatment option I wouldn’t have had access to, and I had an incredible response to Enhertu as my fourth-line of treatment.”
What’s Next for HR+ MBC?
Dr. Jhaveri commented on the importance of optimizing treatment sequencing, the order in which treatments are given. Because there are numerous treatment options available, knowing the best order to give those treatments in could further extend and improve the lives of those living with HR+ MBC.
Additionally, there are new drugs being tested, including a KAT6 inhibitor in the KATSIS-1 trial, a CDK4 inhibitor in the KANDELA-302 trial and atirmociclib in the FourLight-3 trial.
“We just need to continue to do this good work that we’re doing to not lose the finish-line goal, which is how do we make our patients feel better, improve their outcomes, make them live longer, and make them live well,” says Dr. Jhaveri.
Treatment Chemistry: Finding What Works for You
“I view metastatic breast cancer as kind of like we’re dating drugs,” says Bethany. “We go into a line of treatment, that first date, with all the hope in the world that we’re going to get along, able to do all of our favorite things together and have this great life. But we also don’t know if this is going to be a few dates, a summer fling, a couple of years or more long term. “Of course, the hope is we find ‘the one’, that lifetime partner that can keep you ‘no evidence of disease’ for years, and years, and years.”
Subscribe to Komen’s YouTube channel to stay informed about future episodes of Breast Cancer Breakthroughs, where we will delve into the most exciting advances in breast cancer treatment and technology coming soon for patients.
Content covered in the Breast Cancer Breakthroughs educational series may be an emerging area in research or technology. This information is being provided for educational purposes only and is not to be construed as medical advice. Talk to your physician when deciding what is right for you.
Breast cancer can bring questions you never expected to have — and moments when you simply need someone to listen. Komen’s Breast Care Helpline connects you with trained, caring staff who are here to listen, answer questions and help you find the information, resources and support you need. Call 1-877 GO KOMEN (1-877-465-6636) Monday–Thursday, 9 a.m.–7 p.m. ET, and Friday, 9 a.m.–6 p.m. ET, or email helpline@komen.org. Se habla Español.
For more information on clinical trials or if you need support as you go through treatment, the Komen Patient Care Center can help.
Find a clinical trial.
Explore the EMBER-3 Trial Fact Sheet
Take this survey to let us know what you think of this content as part of the Breast Cancer Breakthroughs Series.
Breast Cancer Breakthroughs is possible thanks to our series sponsors:




